India on the verge of becoming clinical trials hub, Parexel executive says

India is poised to become a prominent site for early-stage clinical trials, particularly amid the disruptions caused by the Russia-Ukraine conflict. Parexel plans to increase its Indian workforce by over 2,000 within five years, citing lower costs and growing market potential. However, challenges such as regulatory inconsistencies and awareness regarding experimental treatments remain obstacles.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/yqTQpmU
via IFTTT